Baidu
map

Sci Rep:Fe3O4@MPS@PMAC可灵敏富集糖肽并用于外泌体研究

2017-12-03 MedSci MedSci原创

生物样品中糖肽的低丰度使得在进一步分析之前需要富集它们。在本研究中,通过一步回流沉淀聚合法合成了高分子亲水性离子液体修饰的磁性(Fe3O4@MPS@PMAC)纳米粒子。由于聚合亲水性离子液体[2-(甲基丙烯酰氧基)乙基]三甲基氯化铵(MAC)具有优良的亲水性和对静电作用的强亲和力,所合成的Fe3O4@MPS@PMAC纳米粒子在糖肽富集中表现出优异的检测灵敏度(10fmol),较强的结合能力(100

生物样品中糖肽的低丰度使得在进一步分析之前需要富集它们。在本研究中,通过一步回流沉淀聚合法合成了高分子亲水性离子液体修饰的磁性(Fe3O4@MPS@PMAC)纳米粒子。

由于聚合亲水性离子液体[2-(甲基丙烯酰氧基)乙基]三甲基氯化铵(MAC)具有优良的亲水性和对静电作用的强亲和力,所合成的Fe3O4@MPS@PMAC纳米粒子在糖肽富集中表现出优异的检测灵敏度(10fmol),较强的结合能力(100μgmg-1)和令人满意的富集恢复(约82%)。此外,新制备的Fe3O4@MPS@PMAC纳米粒子被用于HeLa外泌体蛋白的糖肽富集。在50μgHeLa外泌体蛋白质的三次重复分析中共鉴定了来自536个糖蛋白的1274个糖肽。

综上所述,该研究结果证明了Fe3O4@MPS@PMAC纳米粒子用于糖蛋白质组学分析和外泌体研究的潜力。

原始出处:

Fenglong Jiao, Fangyuan Gao, et al., Polymeric hydrophilic ionic liquids used to modify magnetic nanoparticles for the highly selective enrichment of N-linked glycopeptides. Sci Rep. 2017; 7: 6984.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984949, encodeId=fe1819849499f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Tue Mar 13 04:17:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996104, encodeId=07321996104ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 21 10:17:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266543, encodeId=ccf22665432f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Dec 03 22:06:56 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266522, encodeId=63f526652249, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Sun Dec 03 21:19:09 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984949, encodeId=fe1819849499f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Tue Mar 13 04:17:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996104, encodeId=07321996104ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 21 10:17:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266543, encodeId=ccf22665432f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Dec 03 22:06:56 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266522, encodeId=63f526652249, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Sun Dec 03 21:19:09 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2018-02-21 智慧医人
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984949, encodeId=fe1819849499f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Tue Mar 13 04:17:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996104, encodeId=07321996104ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 21 10:17:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266543, encodeId=ccf22665432f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Dec 03 22:06:56 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266522, encodeId=63f526652249, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Sun Dec 03 21:19:09 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 changjiu

    学习一下谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1984949, encodeId=fe1819849499f, content=<a href='/topic/show?id=d3811218054' target=_blank style='color:#2F92EE;'>#MPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12180, encryptionId=d3811218054, topicName=MPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Tue Mar 13 04:17:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996104, encodeId=07321996104ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Feb 21 10:17:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266543, encodeId=ccf22665432f, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sun Dec 03 22:06:56 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266522, encodeId=63f526652249, content=学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Sun Dec 03 21:19:09 CST 2017, time=2017-12-03, status=1, ipAttribution=)]
    2017-12-03 执着追梦

    学习.谢谢分享

    0

相关资讯

ACS Nano:医疗纳米粒子:肺癌的局部治疗

纳米粒子可以作为对抗肺癌药物的载体。NIM(纳米系统倡议者慕尼黑)卓越集群的联合项目,来自亥姆霍兹慕尼黑中心(HMGU)和路德维希 - 马克西米利安大学(LMU)在慕尼黑的科学家已经开发了一种纳米粒子可作为载体的药物,人类和小鼠的肺部肿瘤部位有选择地释放药物。在 “ACS Nano” 杂志中,科学家报告说,这种做法使目前的抗癌药物在肺癌肿瘤组织的有效性显著增加。 纳米颗粒是极其微小的粒子,可将其

Nanoscale.:具有持续药物释放能力的聚(ε-己内酯)纳米载体:用于长期青光眼治疗!

台湾桃园长庚大学生物化学与生物医学工程研究所的Lee CH, 近日在Nanoscale 杂志上发表了一项有趣的工作,标题为"Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment",他们开发持续和长期释放青光眼药物毛果芸香碱

Nat Commun:新型Celastrol-白蛋白纳米粒子或可有效治疗肾小球肾炎

已知肾小球系膜细胞介导的肾小球肾炎是终末期肾病的常见原因。本研究中,研究人员发现,celastrol在大鼠模型中可有效治疗可逆和不可逆的肾小球膜增生性肾小球肾炎,但是celastrol的脱靶分布导致严重的全身毒性反应。 因此,研究人员使用白蛋白纳米颗粒包裹celastrol靶向肾小球系膜细胞。结果显示,大鼠抗Thy1.1肾炎模型中,Celastrol-白蛋白纳米粒子可穿过内皮缝隙并累积在肾小球系膜

新型纳米粒子引导成像可定位并杀死癌细胞

新型纳米粒子引导成像可定位并杀死癌细胞目前科学家正在研究可降解的生物纳米药物,可选择性的破坏卵巢癌术后残留的癌细胞。这些研究发现是研发靶向治疗难治性癌症的一大进步。该研究已于10月25-29日在奥兰多举办2015美国AAPS年会和博览会上展示。据美国癌症协会统计,美国每年约有21290例卵巢癌新发病例,14180名女性死于卵巢癌。目前对于进展性卵巢癌的治疗仅限于手术切除,然后化疗的方法。在无其他治

Hepatology:纳米粒子的靶向递送对肝细胞癌的神奇作用!

肝细胞癌(HCC)是一种侵袭性肿瘤,目前的治疗方式主要为有限的系统性和局部性治疗。尽管基于microRNA(miRNA)的疗法具有显着的潜力,但其靶向递送仍然是目前治疗的主要挑战。 miR-199a-3p在HCC中起着重要的肿瘤抑制剂作用,其调节各种细胞生长过程。近来,基于肽的纳米颗粒(NP)已经被开发用于递送包括miRNA的寡核苷酸。近期,一项发表在杂志Hepatology上的研究描述

Small:双酶-核壳结构的纳米粒子在ATP-H2O2原位顺序检测及成像中的应用

复杂生物样品中的多种指示性分子和生物标记物的检测在疾病诊断和临床治疗中具有十分重要的作用。然而,目前常用的分步检测往往需要重复采样和样品预处理,采样的误差会导致检测结果的准确性低,样品预处理耗时费力。因此,构建背景低,无光漂白效应的新型检测方法,实现同一复杂生物样品中多种待测样品无干扰的原位顺序检测是十分必要的。化学发光是物质在化学反应过程中,释放的能量被某物质分子吸收并跃迁至激发态,由激发态返回

Baidu
map
Baidu
map
Baidu
map